Synlogic reports preclinical data for STING agonist-producing candidate in melanoma

Synlogic Inc. (NASDAQ:SYBX) reported preclinical data from mouse models of melanoma showing that intratumoral SYN-STING significantly reduced tumor growth compared with saline controls (p<0.05). SYN-STING also significantly increased total T cell numbers and activated effector T cells in tumor draining lymph nodes vs. controls...